Find disease awareness content and relevant supporting materials

Recurrent or refractory testicular cancer VEPESID is indicated in combination with other approved chemotherapeutic agents for the treatment of recurrent or refractory testicular cancer in adults. Small cell lung cancer VEPESID is indicated in combination with other approved chemotherapeutic agents for the treatment of small-cell lung cancer in adults. Hodgkin's lymphoma VEPESID is indicated in combination with other approved chemotherapeutic agents for the second line treatment of Hodgkin's lymphoma in adults. Non-Hodgkin's lymphoma VEPESID is indicated in combination with other approved chemotherapeutic agents for the treatment of relapsed or refractory non-Hodgkin's lymphoma in adults. Acute myeloid leukaemia VEPESID is indicated in combination with other approved chemotherapeutic agents for the treatment of relapsed or refractory acute myeloid leukaemia in adults. Ovarian cancer VEPESID is indicated in combination with other approved chemotherapeutic agents for the treatment of non-epithelial ovarian cancer in adults. VEPESID is indicated for the treatment of platinum-resistant/refractory epithelial ovarian cancer in adults.

Recurrent or refractory testicular cancer Etoposide is indicated in combination with other approved chemotherapeutic agents for the treatment of recurrent or refractory testicular cancer in adults. Small cell lung cancer Etoposide is indicated in combination with other approved chemotherapeutic agents for the treatment of small-cell lung cancer in adults. Hodgkin's lymphoma Etoposide is indicated in combination with other approved chemotherapeutic agents for the second line treatment of Hodgkin's lymphoma in adults. Non-Hodgkin's lymphoma Etoposide is indicated in combination with other approved chemotherapeutic agents for the treatment of relapsed or refractory non-Hodgkin's lymphoma in adults. Acute myeloid leukaemia Etoposide is indicated in combination with other approved chemotherapeutic agents for the treatment of relapsed or refractory acute myeloid leukaemia in adults. Ovarian cancer Etoposide is indicated in combination with other approved chemotherapeutic agents for the treatment of non-epithelial ovarian cancer in adults. Etoposide is indicated for the treatment of platinum-resistant/refractory epithelial ovarian cancer in adults.

For the treatment of vitamin D deficiency (serum 25(OH)D <25 nmol/l). STRIVIT-D3 is indicated in adults and the elderly.

Prevention and treatment of vitamin D deficiency in adults and adolescents with an identified risk. As an adjunct to specific therapy for osteoporosis in patients with vitamin D deficiency or at risk of vitamin D insufficiency.

Prevention and treatment of vitamin D deficiency. As an adjunct to specific therapy for osteoporosis in patients with vitamin D deficiency or at risk of vitamin D insufficiency. Colecalciferol is indicated in adults, the elderly and adolescents.

Prophylaxis and treatment of vitamin D deficiency in adults and adolescents with an identified risk. In addition to specific osteoporosis treatment of patients who are at risk of vitamin D deficiency, preferably in combination with calcium.

Prophylaxis and treatment of vitamin D deficiency in adults and adolescents with an identified risk. In addition to specific osteoporosis treatment of patients who are at risk of vitamin D deficiency, preferably in combination with calcium.

Transplantation indications Solid organ transplantation Prevention of graft rejection following solid organ transplantation. Treatment of transplant cellular rejection in patients previously receiving other immunosuppressive agents. Bone marrow transplantation Prevention of graft rejection following allogeneic bone marrow and stem cell transplantation. Prevention or treatment of graft-versus-host disease (GVHD). Non-transplantation indications Endogenous uveitis Treatment of sight-threatening intermediate or posterior uveitis of non-infectious aetiology in patients in whom conventional therapy has failed or caused unacceptable side effects. Treatment of Behçet uveitis with repeated inflammatory attacks involving the retina in patients without neurological manifestations. Nephrotic syndrome Steroid-dependent and steroid-resistant nephrotic syndrome, due to primary glomerular diseases such as minimal change nephropathy, focal and segmental glomerulosclerosis, or membranous glomerulonephritis. Neoral can be used to induce and maintain remissions. It can also be used to maintain steroid-induced remission, allowing withdrawal of steroids. Rheumatoid arthritis Treatment of severe, active rheumatoid arthritis. Psoriasis Treatment of severe psoriasis in patients in whom conventional therapy is inappropriate or ineffective. Atopic dermatitis Neoral is indicated in patients with severe atopic dermatitis when systemic therapy is required.

One-Alpha* is indicated in all conditions where there is a disturbance of calcium metabolism due to impaired 1-α hydroxylation such as when there is reduced renal function. The main indications are: a) Renal osteodystrophy b) Hyperparathyroidism (with bone disease) c) Hypoparathyroidism d) Neonatal hypocalcaemia e) Nutritional and malabsorptive rickets and osteomalacia f) Pseudo-deficiency (D-dependent) rickets and osteomalacia g) Hypophosphataemic vitamin D resistant rickets and osteomalacia

Ethosuximide 250 mg Capsules, soft gives selective control of absence seizures (petit mal) even when complicated by grand mal. It is also indicated for myoclonic seizures.